注册本刊作者作者投稿查稿
专家远程审稿编辑在线审稿
编务办公专区主编办公专区
下载文档
工作动态
联系方式
发行周期:
月刊
主管单位:
上海市卫生健康委员会
主办单位:
上海市医学会
编辑出版:
《上海医学》编辑部
联系地址:
上海市北京西路1623号
邮编:
200040
电话:
021-62178606
传真:
021-62178606
邮箱:
smasmj@shsma.org.cn
ISSN:
ISSN0253-9934
CN:
CN31-1366/R
收款账号:
1001255309008900719
账户名:
上海市医学会
开户行:
工商银行上海市静安寺支行
友情链接

当前位置：首页 > 过刊浏览->2012年第3期

吉西他滨联合奥沙利铂治疗尿路上皮肿瘤的临床研究
Clinical observation of gemcitabine combined with oxaliplatin in the treatment for urothelial cancer

浏览(2456) 下载(0)

DOI:
作者:
孙忠全
SUN Zhong-quan
作者单位:
复旦大学附属华东医院 泌尿外科
Department of Urology, Hua Dong Hospital, Fu Dan University
关键词:
尿路上皮肿瘤； 癌； 吉西他滨； 奥沙利铂； 联合化疗
Urothelial tumor ; cancer ; gemcitabine ; oxaliplatin ; combination chemotherapy
摘要:
目的：观察吉西他滨联合奥沙利铂治疗尿路上皮癌疗效和安全性。方法： 31例有可测量或不可测量病灶患者（男28例，女3例）采用GEMOX方案治疗：吉西他滨1250mg/ m2，第1、8天，奥沙利铂100 mg/ m2，第2天，21天为一周期。每个周期评价安全性，2个周期评价疗效，如无无法耐受的毒副反应，一般最多用6个周期。以RECIST实体瘤评价标准评价疗效，以WHO标准评价安全性。结果： 31例共完成个周期104（1~9个周期），27例可评价疗效，完全缓解5例，部分缓解11例，有效率为59.3%，完全缓解率为18.5%。31例均可评价毒副反应，主要毒副反应为骨髓抑制、疲乏和外周神经毒性，WHOⅢ~Ⅳ度毒副反应15例，其中中性粒细胞细胞减少4例，血小板减少6例，疲乏3例，肝功能损害1例，无肾功能损害。结论：吉西他滨联合奥沙利铂一线治疗尿路上皮癌疗效较好，安全性高，对肾功能无明显影响
Objective: To observe the therapeutic effect and safety of gemcitabine combined with oxaliplatin in the treatment of patients with urothelial cancer. Methods: 31 cases(28 males and 3 females) with measurable or evaluable lesion received a GEMOX treatment: gemcitabine 1250mg/ m2 on day 1 and 8 and oxaliplatin 100 mg/ m2 on day 2 every 21 days. The safety was evaluated every cycle and the therapeutic effect was evaluated every two cycles. If the side-effect was not unbearable, the treatment would last no more than 6 cycles. Standard Response Evaluation Criteria in Solid Tumors (RECIST) criteria were used to assess effect and WHO criteria for safety. Results: The 31 cases received 104 cycles in all (from 1 to 9 cycles). Among them, 27 cases could be evaluated for effect . There were 5 CR(Complete response) and 11 PR (partial response) for an overall response rate of 59.3%. And the complete response rate was 18.5%. All the patients were able to assess toxicity, which mainly included myelosuppression, asthenia and peripheral neuropathy. There were 15 cases of WHO grade Ⅲ~ Ⅳ toxicity. Among them were 4 cases of neutropenia, 6 cases of thrombocytopenia, 3 cases of asthenia and 1 case of hepatotoxicity. There was no renal function impairment. Conclusions: The combination of gemcitabine and oxaliplatin as a fist-line treatment for urothelial cancer could acquire a better therapeutic effect with a greater safety and no renal impairment.

 

主管单位：上海市卫生健康委员会  主办单位：上海市医学会
©2025《上海医学》编辑部 沪ICP备09078599号
您是本站第26803212名访问者
网站管理